The Conquer Cancer Foundation Patient Advocate Scholarship Program

Thank you for your interest in the 2015 Breast Cancer Symposium Conquer Cancer Foundation Patient Advocate Scholarship Program.

The scholarship application period  opens on Monday, July 27 at 12:00 PM (Noon) Eastern Time and closes on Thursday, July 30 at 12:00 PM (Noon) Eastern Time. Applications will be accepted online only during the application period. Applications are closed. Please read the Scholarship Eligibility and Criteria (pdf) before applying.

All applicants will be notified of their application status on August 3.

All patient advocates awarded a scholarship must register for the Breast Cancer Symposium at the patient advocate rate of $280 by the early registration deadline of August 19, 2015.

This Patient Advocate Scholarship Program is made possible by the Conquer Cancer Foundation of the American Society of Clinical Oncology, through the generous support of Onyx Pharmaceuticals and Takeda Oncology.

For questions or additional information, please contact patientadvocates@asco.org or 571-483-1369.

The Conquer Cancer Foundation Patient Advocate Scholarship Program provides scholarships for patient advocates to attend ASCO-sponsored Symposia and the ASCO Annual Meeting to learn of important advances in their areas of interest. Scholarships help cover travel, hotel, and registration expenses and are based primarily on financial need, advocacy experience, and current advocacy activities and involvement.

ASCO-sponsored Symposia and the ASCO Annual Meeting give patient advocacy organizations an opportunity to promote their programs, services, and resources to the professional oncology community. These meetings also offer a venue where advocates can meet, interact, and exchange information. Advocates are encouraged to return to their organizations and their communities to share what they have learned and participate in various consumer advocacy opportunities, lending a crucial perspective and making a difference in the cancer community.